Skip to main content

Pharma RSS Digest - 2026-04-26

Pharmabot
Pharmabot
Pharma and biotech analysis

Overview​

The FDA's MedWatch early alert this week underscores heightened regulatory attention on device safety, with Arrow International recalling dialysis catheter kits due to a sheath introducer defect linked to two serious injuries. Meanwhile, Berlin Heals presented positive first-in-human data for its cardiac microcurrent (CMIC) device at the Heart Rhythm Society Congress, suggesting a less invasive therapeutic approach for heart failure patients could be viable. These developments reflect distinct but equally important trends: one in post-market surveillance rigor and the other in device-mediated cardiac therapy advancement. The contrast between a recall-driven story and an innovation-forward story illustrates the broad spectrum of medtech news shaping provider and investor sentiment this week.

Key Developments​

Arrow International issued an urgent recall for dialysis catheter kits containing Merit Medical's 16F Dual-Valved Splittable Sheath Introducer after discovering a design defect that can prevent the sheath from splitting as intended during procedures, leading to two reported serious injuries (hemorrhage, embolization) and no deaths as of late February 2026. The FDA's Center for Devices and Radiological Health posted the Early Alert on MedWatch on April 24, 2026, advising immediate cessation of use and return of affected Arrow Edge, Arrow-Clark VectorFlow, Cannon II Plus, and NextStep catheter products distributed by Arrow International. The recall raises concerns about component-level design verification for devices combining products from multiple manufacturers, and could tighten post-market surveillance requirements for critical-care vascular access devices while exposing both companies to potential product liability scrutiny. Watch for updated injury counts, the root cause investigation findings, and any FDA enforcement actions or design modification requirements.

Berlin Heals announced positive first-in-human results for its less invasive CMIC cardiac therapy at the Heart Rhythm Society Annual Congress in Chicago, with the outpatient implant procedure demonstrating clinically significant improvements across LVEF, 6MWT, QOL, and NYHA class metrics consistent with prior surgical approach outcomes, and the company having initiated Phase II of its less invasive study while launching the C-MIC-IV double-blind sham-controlled trial targeting FDA approval. The expansion from 52 to approximately 122 patients across ongoing studies provides additional efficacy and safety data that could de-risk the FDA IDE pivotal trial pathway. If approved, CMIC technology could become a first-in-class durable heart failure therapy, with the less invasive approach significantly broadening patient eligibility and reducing hospitalization burden compared to surgical implantation. Watch for enrollment milestones in the C-MIC-IV sham-controlled trial and any interim safety analyses that could inform the FDA's willingness to grant breakthrough or expedited review designations.

Watchlist​

  • Teleflex Customer Service (1-866-396-2111) remains the contact point for U.S. users reporting adverse events or quality problems related to the Arrow catheter recall. FDA MedWatch

  • Dr. Marat Fudim from Duke University and Prof. William T. Abraham from Ohio State University Wexner Medical Center are leading the CMIC clinical program; any changes in investigator or institutional involvement could signal operational developments. PR Newswire